The company is grappling with losing Humira's patent protection in 2023.
The acquisition fills an immediate need with some extras to boot.
It's making a major acquisition to beef up a key area of its pipeline.
The big drugmaker went on a holiday shopping spree.
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.
AbbVie's business could soon become more diversified.
The company announces a major deal worth over $10 billion.
AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales
VANCOUVER – Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their “Cancer Moonshot” initiative, an ambitious plan to slash cancer rates in half within...